Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly reduced sleep-related and dopaminergic side effectsData analysis also confirmed patients treated with P2B001 developed significantly less new-onset excessive daytime sleepiness when compared to marketed pramipexole
Pharma Two B to Present Additional Positi... - Cure Parkinson's
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Benfotiamine In The Mix For PD Again?
< 0.001) when compared with the BFT per se; (p < 0.001) when compared with the low dose of BFT; (p...
Anyone else trying ibogaine?
I started a low dose regime of ibogaine a few days ago and the results are remarkable in just a few...
Parkinson’s and vagal nerve stimulation, promising human studies.
RESULTS: PD patients showed instable gait with insufficient range of motion during usual walking....
Another Potential Benefit Of Melatonin for PwP
of cataract compared with the general older population, which if left untreated can result in poor...
Researchers discover a potential cause of Parkinson's disease
In 2021, Professor Per Saris's group published results demonstrating that bacteria of the...
Virtual Reality Training Improves Balance for Patients With Parkinson Disease
crying out loud for help..
Prayers Answered, TTFD in small doses - Thiamine (B1) Therapy works.
Phase 3 Positive Topline Results for Tavapadon 
